Effects of pharmacogenomic (PGx) testing on clinical pain management prescriptions, a retrospective study

Data Availability

This study was conducted in accordance with the Declaration of Helsinki with written informed consent from each patient. Patient data collection and summaries were approved by the Alcala Pharmaceutical Inc. Institutional Review Board (IORG0010127, IRB00012026, #R003). All test samples derived from human subjects were de-identified of their health information as defined by HIPAA guidelines. Patient data for comparison of urine drug adherence testing before and after PGx reporting were obtained retrospectively from patients (n = 171) during routine testing in a pain management clinic representing an ethnically diverse patient population served by Alcala Testing and Analysis Services (ATAS) from 2016 to 2018 within the western United States. Available data includes de-identified pre- and post-PGx medication lists, PGx and urine drug adherence data.